Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer

Journal of Surgical Oncology

Volumn 102, Issue 7, 2010, Pages 852-855

  Yano, Tokujiro ^a   Haro, Akira ^a   Yoshida, Tsukihisa ^a   Morodomi, Yosuke ^a   Ito, Kensaku ^a   Shikada, Yasunori ^a   Shoji, Fumihiro ^a   Maruyama, Riichiroh ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

disease free interval; local therapy; non small cell lung cancer; oligometastases; postoperative recurrence

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE INTERVAL; FEMALE; HUMAN; LUNG LOBECTOMY; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSTOPERATIVE PERIOD; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 78649671323     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21750     Document Type: Article

References (26)

1. Mountain CF:, Revisions in international staging system for lung cancer. Chest 1997; 111: 1710-1717. (Pubitemid 27260107)
2. Goya T, Asamura H, Yoshimura H, et al.: Prognosis of 6644 resected non-small cell lung cancers in Japan: A Japanese lung cancer registry study. Lung Cancer 2005; 50: 227-234.
3. Ichinose Y, Yano T, Yokoyama H, et al.: Postrecurrent survival of patients with non-small-cell lung cancer undergoing a complete resection. J Thorac Cardiovasc Surg 1994; 108: 158-161.
4. Williams BA, Sugimura H, Endo C, et al.: Predicting postrecurrence survival among completely resected nonsmall-cell lung cancer patients. Ann Thorac Surg 2006; 81: 1021-1027.
5. Sugimura H, Nichols FC, Yang P, et al.: Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg 2007; 83: 409-417.
6. Yano T, Hara N, Ichinose Y, et al.: Local recurrence after complete resection for non-small cell carcinoma of the lung: Significance of local control by radiation treatment. J Thorac Cardiovasc Surg 1994; 107: 8-12.
7. MacDermed DM, Weichselbaum RR, Salama JK:, A rational for the targeted treatment of oligometastases with radiotherapy. J Surg Oncol 2008; 98: 202-206.
8. Hishida T, Nagai K, Yoshida J, et al.: Is surgical resection indicated for a solitary non-small cell lung cancer recurrence ? J Thorac Cardiovasc Surg 2006; 131: 838-842.
9. Yano T, Shoji F, Maehara Y:, Current status of pulmonary metastasectomy from primary epithelial tumors. Surg Today 2009; 39: 91-97.
10. Martini N, Melamed MR:, Multiple primary lung cancers. J Thorac Cardiovasc Surg 1975; 606-612.
11. Antakli T, Schaefer RF, Rutherford BS, et al.: Second primary lung cancer. Ann Thorac Surg 1995; 59: 863-867.
12. Yano T, Yokoyama H, Inoue T, et al.: The first site of recurrence after complete resection in non-small-cell carcinoma of the lung. J Thorac Cardiovasc Surg 1994; 108: 680-683.
13. Yano T, Yokoyama H, Inoue T, et al.: Surgical results and prognostic factors of pathologic N1 disease in non-small-cell carcinoma of the lung. Significance of N1 level; lobar or hilar nodes. J Thorac Cardiovasc Surg 1994; 107: 1398-1402.
14. Non-small cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995; 311: 899-909.
15. Hellman S, Weichselbaum RR:, Oligometastases. J Clin Oncol 1995; 13: 8-10.
16. Walsh GL, O'Connor M, Willis KM, et al.: Is follow-up of lung cancer patients after resection medically indicated and cost-effective ? Ann Thorac Surg 1995; 60: 1563-1570. (Pubitemid 26078243)
17. Mitsudomi T, Nishioka K, Maruyama R, et al.: Kinetic analysis of recurrence and survival after potentially curative resection of nonsmall cell lung cancer. J Surg Oncol 1996; 63: 159-165.
18. Wakelee HA, Chang ET, Gomez SL, et al.: Lung cancer incidence in never smokers. J Clin Oncol 2007; 25: 472-478.
19. Yano T, Miura N, Takenaka T, et al.: Never-smoking non-small cell lung cancer as a separate entitya - The clinico-pathologic features and survival. Cancer 2008; 113: 1012-1018.
20. Scagliotti GV, De Marinis F, Rinaldi M, et al.: Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol 2002; 20: 4285-4291.
21. Schiller JH, Harrington D, Belani CP, et al.: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346: 92-98.
22. Kim ES, Hirsh V, Mok T, et al.: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 2008; 372: 1809-1818.
23. Rosell R, Moran T, Queralt C, et al.: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-967.
24. Jackman DM, Miller VA, Cioffredi LA, et al.: Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: Results of an online tumor registry of clinical trials. Clin Cancer Res 2009; 15: 5267-5273.
25. Mitsudomi T, Kosaka T, Endoh H, et al.: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23: 2513-2520.
26. Mok TS, Wu YL, Thongprasert S, et al.: Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.